Cardiovascular Disease

ADHD Meds & Cardiovascular Disease

A meta-analysis of nearly 4M participants found no association between the use of medications to treat ADHD and any cardiovascular disease outcome. 

ADHD medications are known to increase heart rate and blood pressure, and as the use of ADHD medication increases in both adults and children, there has been understandable concern that ADHD meds may lead to adverse cardiovascular effects. 

But these findings suggest these medications may actually be safe for the heart. 

In the systematic review and meta-analysis, researchers analyzed 19 studies from the US, Spain, Denmark, Hong Kong, Canada, and South Korea, involving 3.9M children, adolescents, and adults. 

Researchers found no statistically significant association between ADHD and any CVD outcome among…

  • Children and adolescents (pooled adjusted relative risk: 1.18)
  • Young or middle-aged adults (RR: 1.04)
  • Older adults (RR: 1.59)

Both stimulants and non-stimulants showed no association. When the authors looked at specific cardiovascular outcomes (such as cardiac arrest, arrhythmias, cerebrovascular diseases, or myocardial infarction) there was still no association. There was even no association among those with preexisting CVD.  

The Takeaway

Overall, the findings are reassuring and suggest these medications — which have raised concerns about CVD risk — may be safe for the heart. While the authors acknowledge that a “modest risk increase could not be ruled out,” the findings should comfort readers with cardiovascular patients being treated for ADHD.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiovascular Disease August 4, 2025

The Impact of Physical Activity Before and After CV Events August 4, 2025

A long-term analysis of the CARDIA study revealed that moderate-to-vigorous physical activity steadily declines from young adulthood through midlife, but patients destined to develop cardiovascular disease experience rapid activity decreases more than a decade before their first event. Collecting data over 37 years, researchers tracked ~3k participants from young adulthood to middle age and paired […]

Cardiology Pharmaceuticals July 31, 2025

AstraZeneca’s Anselamimab Comes Up Short in Phase 3 Trial July 31, 2025

In a setback to one of its rarer disease pipelines, AstraZeneca’s amyloidosis antibody, anselamimab, failed to significantly reduce all-cause mortality and CV hospitalizations in the CARES Phase 3 trial’s overall patient population.  The CARES clinical program was the largest prospective cardiac AL amyloidosis investigation to date, enrolling 406 patients to test whether anselamimab could reduce […]

Cardiology Pharmaceuticals July 28, 2025

SGLT2i Prescriptions Increase for HF, With Some Exceptions July 28, 2025

Three years after SGLT2 inhibitors were added to the heart failure treatment guidelines, a JAMA Cardiology study reveals significant new prescriptions, with a few key patient sub-groups falling behind. Researchers analyzed prescribing patterns of SGLT2 inhibitors for 760k HF patients in the National Cardiovascular Data Registry and found significant and rapid uptake in the last […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!